The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | D | Dermatologicals | |
| 2 | D07 | Corticosteroids, dermatological preparations | |
| 3 | D07A | Corticosteroids, plain | |
| 4 | D07AC | Corticosteroids, potent (group III) | |
| 5 | D07AC17 | Fluticasone |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| RESPIR - Respiratory (Inhalation) (aerosol) | 0.6 mg |
| RESPIR - Respiratory (Inhalation) (powder) | 0.6 mg |
| Active Ingredient | Description | |
|---|---|---|
| Fluticasone |
Fluticasone has anti-inflammatory and vasoconstrictive features. Fluticasone given by inhalation at recommended doses has a potent glucocorticoid anti-inflammatory action within the lungs, resulting in a reduction of both symptoms and exacerbations of asthma, with a lower incidence and severity of adverse effects than those observed when corticosteroids are administered systemically. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| CUTIVATE Lotion | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| FLIXOTIDE EVOHALER Pressurised inhalation, suspension | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
